ES2006941A6 - Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii). - Google Patents

Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii).

Info

Publication number
ES2006941A6
ES2006941A6 ES8801494A ES8801494A ES2006941A6 ES 2006941 A6 ES2006941 A6 ES 2006941A6 ES 8801494 A ES8801494 A ES 8801494A ES 8801494 A ES8801494 A ES 8801494A ES 2006941 A6 ES2006941 A6 ES 2006941A6
Authority
ES
Spain
Prior art keywords
peptide
iii
producing
human
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8801494A
Other languages
English (en)
Inventor
Shiu-Lok Hu
Anthony F Purchio
Linda Madisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of ES2006941A6 publication Critical patent/ES2006941A6/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN METODO DE PRODUCIR UN PEPTIDO O UNA PROTEINA RELACIONADOS CON UN EPITOPE DE VIRUS ASOCIADO A LINFOADENOPATIAS/VIRUS DE LEUCEMIA DE CELULAS T HUMANAS (LAV/HTLV-III), EN EL QUE SE PURIFICA EL PEPTIDO O LA PROTEINA A PARTIR DE UNA CELULA CULTIVADA QUE CONTIENE UNA SECUENCIA DE NUCLEOTIDOS QUE CODIFICA EL PEPTICO O LA PROTEINA DE LAV/HTLV-III BAJO EL CONTROL DE UNA SEGUNDA SECUENCIA DE NUCLEOTIDOS QUE REGULA LA EXPRESION DEL GEN DE MODO QUE EL EPITOPE ES EXPRESADO POR LA CELULA CULTIVADA. EL INVENTO ES ESPECIALMENTE UTIL EN RELACION CON VACUNAS E INMUNOENSAYOS PARA EL SINDROME DE INMUNODEFICIENCIA ADQUIRIDA (SIDA).
ES8801494A 1985-09-25 1988-05-13 Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii). Expired ES2006941A6 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27
US90521786A 1986-09-09 1986-09-09

Publications (1)

Publication Number Publication Date
ES2006941A6 true ES2006941A6 (es) 1989-05-16

Family

ID=27419757

Family Applications (2)

Application Number Title Priority Date Filing Date
ES8602123A Expired ES2002490A6 (es) 1985-09-25 1986-09-24 Un metodo de preparar un virus recombinante
ES8801494A Expired ES2006941A6 (es) 1985-09-25 1988-05-13 Un metodo de producir un peptido o una proteina relacionados con un epitope de virus asociado a linfoadenopatiasnvirus de leucemia de celulas t humanas (lavnhtlv-iii).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES8602123A Expired ES2002490A6 (es) 1985-09-25 1986-09-24 Un metodo de preparar un virus recombinante

Country Status (22)

Country Link
CN (1) CN1020752C (es)
AT (1) ATA256786A (es)
CH (1) CH676247A5 (es)
DE (1) DE3690508T1 (es)
DK (1) DK455486A (es)
ES (2) ES2002490A6 (es)
FI (1) FI863848L (es)
FR (1) FR2587720A2 (es)
GB (1) GB2181435B (es)
GR (1) GR862412B (es)
HU (1) HU205780B (es)
IE (1) IE59314B1 (es)
IL (1) IL80073A (es)
IT (1) IT1195829B (es)
MY (1) MY103182A (es)
NL (1) NL8602422A (es)
NO (1) NO863803L (es)
NZ (1) NZ217645A (es)
PT (1) PT83434B (es)
SE (4) SE8604007L (es)
WO (1) WO1987002038A1 (es)
YU (1) YU46753B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986006099A1 (en) * 1985-04-08 1986-10-23 Genetic Systems Corporation EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
ATE107861T1 (de) * 1986-09-19 1994-07-15 Oncogen Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
IL84154A0 (en) * 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン　コーポレーション 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
ES2104556T3 (es) * 1987-01-16 1997-10-16 Pasteur Institut Peptidos que tienen propiedades inmunologicas de hiv-2.
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
GB8714802D0 (en) * 1987-06-24 1987-07-29 Proteus Biotech Ltd Synthetic polypeptides
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
ES2059823T3 (es) * 1988-05-06 1994-11-16 Ferropas Ag Metodos y sistemas para producir antigenos de hiv.
US5043262A (en) * 1988-05-12 1991-08-27 Dana Farber Cancer Institute Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
AP129A (en) * 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5747324A (en) * 1988-06-10 1998-05-05 Therion Biologics Corporation Self-assembled, defective, non-self-propagating lentivirus particles
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5631154A (en) * 1988-06-10 1997-05-20 Therion Biologics, Incorporated Self assembled, defective, non-self-propagating lentivirus particles
WO1989012095A1 (en) * 1988-06-10 1989-12-14 Applied Biotechnology, Inc. A method of evaluating recombinant vaccines against immunodeficiency virus
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69031735T2 (de) * 1989-04-18 1998-03-12 Applied Biotechnology Inc Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
EP1288304A3 (en) * 1989-06-01 2006-04-05 Applied Biotechnology, Inc. Self-assembled, defective, non-self-propagating viral particles
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5981276A (en) * 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5840312A (en) * 1991-05-02 1998-11-24 Institut Pasteur Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein
FR2676068B1 (fr) * 1991-05-02 1994-11-04 Pasteur Institut Souches recombinantes immunogenes de b. anthracis - compositions immunogenes les contenant.
AU672372B2 (en) * 1991-11-08 1996-10-03 Pharmacia & Upjohn Company Feline leukemia virus vaccines
ATE220327T1 (de) 1992-09-29 2002-07-15 Inhale Therapeutic Syst Pulmonale abgabe von aktiven fragmenten des parathormons
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
JPH11511112A (ja) 1995-02-10 1999-09-28 ユニバーシティ・オブ・マサチューセッツ 外因性化合物の送達
US6013506A (en) * 1995-06-05 2000-01-11 Wardley; Richard C. Feline leukemia virus vaccines
DE59507617D1 (de) * 1995-09-06 2000-02-17 Schablonentechnik Kufstein Ag Verfahren zum Herstellen einer Siebdruckschablone
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6723558B1 (en) 1996-01-23 2004-04-20 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (de) * 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
US4662514A (en) * 1983-11-01 1987-05-05 Charleswater Products, Inc. Electrically conductive polymeric tubes for static sensitive electronic devices
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
WO1986002383A1 (en) * 1984-10-18 1986-04-24 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
AU600658B2 (en) * 1984-12-24 1990-08-23 Genentech Inc. Molecularly cloned acquired immunodeficiency syndrome polypeptides and their methods of use
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
FI861626A7 (fi) * 1985-04-19 1986-10-20 Hoffmann La Roche Foervaervat immunbristsyndrom (aids) -relaterat viralt rekombinant hoeljeprotein samt ett testfoerfarande foer aids.
FR2586427B1 (fr) * 1985-08-20 1988-12-09 Pasteur Institut Sequences de nucleotides et de polypeptides issus du virus visna et leur application a des essais de diagnostic et a la production de compositions immunogenes

Also Published As

Publication number Publication date
GB2181435A (en) 1987-04-23
FI863848A7 (fi) 1987-03-26
IL80073A (en) 1995-01-24
CH676247A5 (es) 1990-12-28
GB8622987D0 (en) 1986-10-29
GB2181435B (en) 1990-01-10
WO1987002038A1 (en) 1987-04-09
FR2587720B2 (es) 1995-02-10
DK455486A (da) 1987-03-26
IT1195829B (it) 1988-10-27
PT83434B (pt) 1988-07-29
IT8667730A0 (it) 1986-09-24
FI863848L (fi) 1987-03-26
FR2587720A2 (fr) 1987-03-27
SE8604007L (sv) 1987-03-26
FI863848A0 (fi) 1986-09-24
NL8602422A (nl) 1987-04-16
SE9102974D0 (sv) 1991-10-14
SE9102976L (sv) 1993-04-15
SE9102976D0 (sv) 1991-10-14
IL80073A0 (en) 1986-12-31
ES2002490A6 (es) 1988-08-16
ATA256786A (de) 1995-05-15
DE3690508T1 (es) 1988-06-23
SE9102974L (sv) 1993-04-15
HUT42133A (en) 1987-06-29
MY103182A (en) 1993-05-29
NO863803D0 (no) 1986-09-24
CN1020752C (zh) 1993-05-19
PT83434A (en) 1986-10-01
DK455486D0 (da) 1986-09-24
CN86106632A (zh) 1987-05-13
NO863803L (no) 1987-03-26
HU205780B (en) 1992-06-29
YU165486A (en) 1989-08-31
GR862412B (en) 1987-01-23
SE9102975L (sv) 1993-04-15
NZ217645A (en) 1991-11-26
IE862525L (en) 1987-03-25
SE9102975D0 (sv) 1991-10-14
YU46753B (sh) 1994-05-10
SE8604007D0 (sv) 1986-09-23
IE59314B1 (en) 1994-02-09

Similar Documents

Publication Publication Date Title
MY121185A (en) Recombinant antibodies for human therapy.
DE3382694D1 (de) Expression, bearbeitung und ausscheidung von heterologem protein durch hefen.
UA32548C2 (uk) Ізольована послідовність днк, що кодує epsps фермент, ізольована послідовність днк, що кодує білок, який виявляє epsps активність, рекомбінантна двониткова молекула днк, спосіб одержання генетично трансформованих рослин
DE3770755D1 (de) Polyimidmembrane zur gastrennung.
NO913186D0 (no) Fremgangsmaate for anvendelse og syntese av peptider.
DE3888489D1 (de) Polyimid-Membranen zur Gastrennung.
DE3587627D1 (de) Composite-Membranen zur Gastrennung.
NO875315D0 (no) Fremgangsmaate for separering av hydrokarbongasser.
AU1986588A (en) Growth hormone receptor
DE3768997D1 (de) Gastrenn-membranen aus polyimid.
DE3873337D1 (de) Aetzverfahren mittels gasplasma.
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
CH0229046H1 (de) Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech
DE3763404D1 (de) Abscheidung von quecksilber aus erdgas.
EP0370458A3 (en) Synthetic DNA derived recombinant HIV-1 antigens
NO852567L (no) Thymopentinanaloger og fremgangsmmaate for deres fremstilling.
OA08413A (en) Monoclonal antibodies against proteins encoded by the genomic RNA of lymphadenopathy-associated-virus (LAV) and hybridomas secreting said antibodies.
CA2004478A1 (en) Monoclonal antibodies to feline-t-lymphotropic lentivirus
DE3784344D1 (de) Funkenbearbeitung durch elektrodengeradelegung.
DE68916558D1 (de) Filmherstellung, zum Beispiel von amorphem Silizium.
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
FI803872A7 (fi) Syklinen peptidi.
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DE3871462D1 (de) Membran zur gastrennung.
DE68918712D1 (de) Rekombinante Eimeria tenella-Vakzine.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000601